| 中文名 | DPHE-HIS-LEU-LEU-ARG-GLU-VAL-LEU-GLU-NLE-ALA-ARG-ALA-GLU-GLN-LEU-ALA-GLN-GLU-ALA-HIS-LYS-ASN-ARG-LYS-LEU-NLE-GLU-ILE-ILE-NH2 |
|---|---|
| 英文名 | astressin |
| 中文别名 |
收敛素
阿斯瑞辛 NLE-ASTRESSIN拮抗剂多肽 |
| 英文别名 |
L-Isoleucinamide,D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-ginyl-L-a-glutamyl-L-valyl-L-leucyl-L-a-glutamyl-L-norleucyl-L-alanyl-L-ginyl-L-alanyl-L-a-glutamyl-L-glutaminyl-L-leucyl-L-alanyl-L
D-PHE-HIS-LEU-LEU-G-GLU-VAL-LEU-GLU-NLE-ALA-G-ALA-GLU-GLN-LEU-ALA-GLN-GLU-ALA-HIS-LYS-ASN-G-LYS-LEU-NLE-GLU-ILE-ILE-NH2 D-Phe-His-Leu-Leu-g-Glu-Val-Leu-Glu-Nle-Ala-g-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-g-Lys-Leu-Nle-Glu-Ile-Ile-NH2 (LactaM bridge Glu30-Lys33) Astressin trifluoroacetate salt H-D-Phe-His-Leu-Leu-g-Glu-Val-Leu-Glu-Nle-Ala-g-Ala-Glu-Gln-Leu-Ala-Gln-cyclo(-Glu-Ala-His-Lys)-Asn-g-Lys-Leu-Nle-Glu-Ile-Ile-NH2 trifluoroacetate salt M.W. 3563.24 C161H269N49O42 [D-PHE12, NLE21,38, GLU30, LYS33]-CRF (HUMAN, RAT) ASTRESSIN (HUMAN, RAT) C161H269N49O42 Astressin >= (HPLC) (D-PHE12,NLE21,38,GLU30,LYS33)-CRF (HUMAN, RAT) TRIFLUOROACETATE SALT H-D-Phe-His-Leu-Leu-g-Glu-Val-Leu-Glu-Nle-Ala-g-Ala-Glu-Gln-Leu-Ala-Gln-cyclo(-Glu-Ala-His-Lys)-Asn-g-Lys-Leu-Nle-Glu-Ile-Ile-NH2 L-Isoleucinamide, D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-ginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-ginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-α-glutamyl-L-alanyl-L-histidyl-L-lysyl-L-aspaginyl-L-ginyl-L-lysyl-L-leucyl-L-norl (D-PHE12,NLE21,38,GLU30,LYS33)-CRF (HUMAN, RAT) (CYCLIZED BETWEEN GAMMA-GLU30 ANDSILON-LYS33) DPHE-HIS-LEU-LEU-G-GLU-VAL-LEU-GLU-NLE-ALA-G-ALA-GLU-GLN-LEU-ALA-GLN-GLU-ALA-HIS-LYS-ASN-G-LYS-LEU-NLE-GLU-ILE-ILE-NH2 [D-PHE12, NLE21,38, GLU30, LYS33]-CRF , CYCLIC LACTAM, HUMAN, RAT ASTRESSIN TRIFLUOROACETATE SALT ASTRESSIN L-Isoleucinamide, D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-ginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-ginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-α-glutamyl-L-alanyl-L-histidyl-L-lysyl-L-aspaginyl-L-ginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-L-isoleucyl-, cyclic (19→22)-ptide [D-PHE12,NLE21,38,GLU30,LYS33]-CORTICOTROPIN RELEASING FACTOR FRAGMENT H-D-PHE-HIS-LEU-LEU-G-GLU-VAL-LEU-GLU-NLE-ALA-G-ALA-GLU-GLN-LEU-ALA-GLN-CYCLO(-GAMMA-GLU-ALA-HIS-SILON-LYS)-ASN-G-LYS-LEU-NLE-GLU-ILE-ILE-NH2 Astressin [D-PHE12, NLE21,38, GLU30, LYS33]-CORTICOTROPIN RELEASING FACTOR (HUMAN, RAT) [D-Phe12,Nle21,38,Glu30 |
| 描述 | Astressin是有效的促肾上腺皮质激素释放因子 (CRF) 拮抗剂。 |
|---|---|
| 相关类别 | |
| 体外研究 | Astressin对CRF结合蛋白的亲和力低,对克隆的垂体受体具有高亲和力(Ki = 2 nM)。 Astressin对CHO细胞中稳定表达的克隆人CRF-RA1具有高亲和力,并且具有抑制ACTH分泌的高效力[1]。 |
| 体内研究 | 在应激或肾上腺切除的大鼠中,Astressin比任何先前测试的拮抗剂在降低垂体促肾上腺皮质激素(ACTH)分泌方面明显更有效。静脉注射低剂量的astressin(30μg和100μg/ kg)仍然分别在45和90分钟时显着降低ACTH水平[1]。 Astressin显着逆转社交应激和ICV大鼠/人类CRF(r/hCRF)对高架十字迷宫引起的致焦虑样反应,但未能在熟悉的环境中阻断r/hCRF诱导的运动活动的影响[2] ]。在癫痫发作前30分钟和癫痫发作后10分钟,脑室内输注肽可使一些海马细胞区的损伤降低多达84%,其保护程度大于其他CRF拮抗剂对其他坏死性神经元损伤模型的报道。即使在激素毒素暴露后仅10分钟给药,Astressin也会起作用[3]。 |
| 动物实验 | 大鼠:大鼠饮食补充橙子,其水含有0.9%NaCl。它们在静脉注射载体或astressin之前48小时配备留置颈静脉插管。首先将Astressin在无菌,蒸馏的无热水中稀释,并将pH调节至7.0。在含有0.1%牛血清白蛋白和0.01%抗坏血酸的0.04M磷酸盐缓冲液(pH 7.4)中进一步稀释。在治疗前立即获得血液样品,并在15-120分钟后获得。将倾析的血浆样品冷冻直至测定ACTH浓度[1]。 |
| 参考文献 |
| 分子式 | C161H269N49O42 |
|---|---|
| 分子量 | 3563.16000 |
| 精确质量 | 3561.04000 |
| PSA | 1489.66000 |
| LogP | 9.58910 |
| 储存条件 | 2-8℃ |
| 个人防护装备 | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| 危险品运输编码 | NONH for all modes of transport |